Phillipe Moreau
Nantes, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Exploring the impact of dexamethasone on gene regulation in myeloma cells.
Journal: Life science alliance
Published: June 01, 2023
Treatment emergent peripheral neuropathy in the CASSIOPEIA trial.
Journal: Haematologica
Published: January 18, 2022
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Journal: American journal of hematology
Published: March 22, 2021
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Journal: American journal of hematology
Published: March 09, 2021
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: May 26, 2020
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Journal: Leukemia
Published: June 01, 2018
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection.
Journal: Genome medicine
Published: January 07, 2016
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: September 18, 2015
Initial treatment of transplant-eligible patients in multiple myeloma.
Journal: Expert review of hematology
Published: January 08, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026